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Summary Points
• Systematic reviews are most commonly based on aggregate data extracted from publica-
tions or obtained from trial investigators.
• Systematic reviews involving the central collection and analysis of individual participant
data (IPD) usually are larger-scale, international, collaborative projects that can bring
about substantial improvements to the quantity and quality of data, give greater scope in
the analyses, and provide more detailed and robust results.
• The process of collecting, checking, and analysing IPD is more complex than for aggre-
gate data, and not all IPD meta-analyses are done to the same standard, making it diffi-
cult for researchers, clinicians, patients, policy makers, funders, and publishers to judge
their quality.
• Following our step-by-step guide will help reviewers and users of IPD meta-analyses to
understand them better and recognise those that are well designed and conducted and
so help ensure that policy, practice, and research are informed by robust evidence about
the effects of interventions.
Background
Systematic reviews provide an objective and reliable way of summarising research evidence.
They collate all the studies relevant to a particular research question, using explicit, transpar-
ent, and systematic methods in order to minimise bias, and may or may not include a meta-
analysis, to combine the results of these studies. Systematic reviews are most commonly based
on aggregate data extracted from publications or obtained from investigators [1]. These aggre-
gate data represent a summary of the individual participant or patient data (IPD) for each
study and may include, for example, intervention effect estimates (e.g., odds ratios or hazard
ratios) for different outcomes and average patient characteristics (e.g., the mean age of
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participants or the proportion of women). This limits the analyses that are possible and may
also reduce power. Moreover, the availability and quality of such data may vary across studies,
and this can affect the reliability of meta-analysis results [2].
Systematic reviews and meta-analyses of IPD have most commonly been large-scale, inter-
national, collaborative projects involving the central collection and reanalysis of the original
data on each participant, from all of the relevant trials [3–5]. Most have focussed on assessing
the efficacy or effectiveness of treatments or other interventions and therefore have been based
on randomised controlled trials (RCTs). The IPD approach not only can bring about substan-
tial improvements to the quantity and quality of data—for example, by including more trials,
participants, and outcomes—but also enables standardisation of outcomes across trials and
detailed data checking (Table 1, [3–5]). IPD also give greater scope and flexibility in the
Table 1. Advantages of using an IPD rather than aggregate data approach to systematic review and
meta-analysis of RCTs.
Aspect of Systematic Review/
Meta-analysis
Advantages of the IPD Approach
Trial inclusion Asking the IPD collaborative group (of trialists and other experts in the
clinical ﬁeld) to supplement the list of identiﬁed trials
Clarify trial eligibility with trial investigators
Data quality Include trials that are unpublished or not reported in full
Include unreported data, e.g., more outcomes per trial and more
complete information on those outcomes, and data on participants
excluded from trials analyses
Check the integrity of trial IPD and resolve any queries with trial
investigators
Derive standardised outcome deﬁnitions across trials or translate
different deﬁnitions to a common scale
Derive standardised classiﬁcations of participant characteristics or their
disease/condition or translate different deﬁnitions to a common scale
Update follow up of time-to-event outcomes beyond that reported
Risk of bias Clarify trial design, conduct, and analysis methods with trial
investigators
Check risk of bias of trial IPD and obtain extra data when necessary
Analysis Analyse all important outcomes
Determine validity of analysis assumptions with IPD, e.g.,
proportionality of hazards for a Cox model
Derive measures of effect directly from the IPD
Use a consistent unit of analysis for each trial
Apply a consistent method of analysis for each trial
Conduct more detailed analysis of time-to-event outcomes, e.g.,
generating Kaplan Meier curves
Achieve greater power for assessing interactions between effects of
interventions and participant or disease/condition characteristics
Conduct more complex analyses not (usually) possible with aggregate
data, e.g., simultaneous assessment of the relationship between
multiple trial and/or participant characteristics and effects of
interventions
Use nonstandard models or measures of effect
Use IPD for secondary clinical questions, e.g., to explore the natural
history of disease, prognostic factors, or surrogate outcomes
Interpretation Discuss the implications for clinical practice and research with a
multidisciplinary group of collaborators including trial investigators who
supplied the data
doi:10.1371/journal.pmed.1001855.t001
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analyses, including, importantly, the ability to investigate whether an intervention is more or
less effective for different types of participant (Table 1, [3–5]). These aspects help provide more
in-depth exploration and more detailed and robust meta-analysis results, which can differ
from those based on aggregate data (e.g., [6–9]). Additionally, collaboration with investigators
supplying trial data can lead to more complete identification of relevant trials and a broader
interpretation and endorsement of the results (Table 1, [3–5]).
Given their considerable advantages, meta-analyses that are based on IPD have been called
the “gold standard” of systematic review [10], and their use to assess the effects of interventions
from RCTs has increased [11], across a range of health care areas [5] and in both higher- and
lower-resource settings. However, the process of collecting, checking, and analysing IPD is
more complex than for aggregate data, and recent evidence suggests that not all IPD meta-anal-
yses are done or reported to the same standard [11,12]. Also, previous guidance, mainly aimed
at systematic reviewers, has considered only some of the biases that can arise in aggregate data
meta-analyses and how the collection of IPD can help resolve such biases and facilitate under-
standing (e.g., [3–5]). These issues can make it difficult for researchers, clinicians, patients, pol-
icy makers, funders, and publishers to judge the quality of IPD meta-analyses. Therefore, it
may hinder their conduct, dissemination, uptake in clinical guidelines [13] policy and practice
and their influence on trials [14]. This guidance will help a variety of stakeholders understand,
appraise, and make best use of IPD meta-analyses that summarise the efficacy of interventions.
Is It Part of a Systematic Review?
A key component of appraising an IPD review or meta-analysis of efficacy is determining
whether it is part of a systematic review [3–5]. Some hallmarks are the following:
• clear research question, qualified by unambiguous eligibility criteria relating to participants,
interventions, comparisons, and outcomes
• systematic and comprehensive search strategy, to ensure that all relevant trials are identified
• consistent approach to data collection, including an explanation of which items were
requested
• assessment of the quality or risk of bias of included trials
To limit bias, ensure transparency, and allow scrutiny, all such methods should have been
prespecified in a protocol, and ideally this would have been registered [15], published, or other-
wise made available for inspection.
Early systematic reviews and meta-analyses based on IPD were commonly described as
“overviews” or “pooled analyses” (e.g., [16,17]), and subsequently, “IPD meta-analysis” became
the preferred term (and is still widely used). However, with the emergence of more ad hoc IPD
meta-analyses [12], researchers have begun to utilise “systematic review and meta-analysis of
IPD” to flag those in the context of a systematic review (e.g., [18]).
Were All Eligible Trials Identified?
Clear eligibility criteria are needed to determine why particular trials were included in an IPD
meta-analysis and, therefore, whether it gives an unbiased or otherwise representative view of
the evidence (Table 2). For example, a review of 31 IPD meta-analyses found that 29% had an
unclear or unduly selective approach to including studies [12]. Of course, there may be situa-
tions in which it is reasonable to exclude relevant trials. For example, for cardiovascular dis-
ease, in which trials are often very large, it may make sense to exclude small trials that would
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Table 2. Biases that can affect systematic reviews andmeta-analyses of IPD and aggregate data (AD), and steps taken to investigate and/or mini-
mise these.
Type of Bias Deﬁnition Steps That Are Taken to Investigate and Minimise Bias
Usual with both
AD and IPD
approaches
Usual with IPD
approach but may
be possible with
AD approach *
Only with
IPD
approach
Study selection
bias
Systematic differences between
results of trials that are and are not
selected for inclusion
Prospectively deﬁne eligibility
criteria
✓
Clarify eligibility with trial protocol
or trialist
✓
Publication bias Systematic differences between
results of trials that are and are not
published
Include all eligible trials
irrespective of publication status
✓
Data availability
bias
Systematic difference between the
results of trials for which data were
and were not available
Include data for all eligible trials ✓
Investigate/discuss the impact of
trials for which data were not
available
✓
Participant
selection bias
Systematic differences between
comparison groups in participant
characteristics that can lead to
differences in prognosis and/or
responsiveness to treatment
(Prevented by random allocation and
allocation concealment)
Clarify the randomisation
methods, i.e., sequence
generation and allocation
concealment with trial protocol or
trialist
✓
Exclude “nonrandomised” trials ✓
Check for unusual allocation
patterns or distributions of
participant characteristics
✓
Exclude trials with inappropriate
allocation
✓
Exclude nonrandomised
participants from trial IPD
✓
Performance and
detection bias
Systematic differences between
comparison groups in the care
received or provided or in how
outcomes are ascertained (Prevented
by blinding study participants, care
givers, and outcome assessors to the
allocated treatment. Note this is not
possible for all interventions, e.g.,
surgery, and is less important for
objective outcomes, e.g., mortality)
Obtain more complete
information on blinding and
outcome assessment from trialist
and/or protocol
✓
Attrition bias Systematic differences between
comparison groups in the dropout or
exclusion of participants (Prevented by
the maintenance of all participants in
the trial and trial analysis)
Include data on all randomised
participants, irrespective of
whether they were included in
trial analyses
✓
Analyse all trials according to the
allocated intervention (“intention
to treat”)
✓
(Continued)
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contribute very little evidence and take considerable effort to obtain. Importantly, the intention
to exclude trials on this sort of basis should form part of the prospective eligibility criteria.
Given the substantial evidence that publication of research studies, including RCTs, is influ-
enced by the nature of study results [19], all relevant published and unpublished trials should
be sought to avoid bias (Table 2). In 11 IPD meta-analyses in cancer, 45 of the 120 included
RCTs were either unpublished or published in non-English language journals, book chapters,
or conference abstracts [20]; the so-called “grey literature.” Not including these trials would
have produced meta-analysis results that were more in favour of the research treatments than
results based on all available trials [20]. Most differences were modest, but in one meta-analy-
sis, there was stronger evidence that postoperative radiotherapy was detrimental to the survival
of patients with non-small cell lung cancer when all trials (hazard ratio = 1.21, 95% CI = 1.05–
1.39, p = 0.001) rather than only fully published trials were included (hazard ratio = 1.13, 95%
CI = 0.95–1.34, p = 0.066). Yet, IPD meta-analyses do not necessarily include trials published
in the grey literature [12], and in the absence of an explicit search strategy (e.g., [21]), it can be
difficult to judge whether all trials were identified. Thus, IPD meta-analyses with inappropri-
ately restrictive or absent eligibility criteria and/or search strategies that do not seek all relevant
trials need to be viewed with caution.
Direct contact with trial investigators, as part of the IPD approach, can help identify trials
that may not be easily identifiable by other forms of searching [3,4] and clarify the eligibility of
individual trials (Table 1, [3–5]). It should be noted, however, that even with researchers’ best
efforts, all trials may not come to light, and the potential for bias remains. For example, in a
systematic review and meta-analysis in which no unpublished trials were identified [22], funnel
plot asymmetry suggested that some small studies might be missing [12].
Were IPD Obtained fromMost Trials?
It may be difficult to obtain IPD for all trials identified, because trial investigators do not
respond, do not have access to the IPD, or refuse to participate. If nonparticipation is born of a
Table 2. (Continued)
Type of Bias Deﬁnition Steps That Are Taken to Investigate and Minimise Bias
Usual with both
AD and IPD
approaches
Usual with IPD
approach but may
be possible with
AD approach *
Only with
IPD
approach
Check for “missing” participants
and unusual patterns of dropout
or exclusion
✓
Prespecify any reasonable
participant exclusions and apply
consistently across trials
✓
Outcome
reporting or
availability bias
Systematic differences between
results of reported/available and
unreported/unavailable outcomes
(Prevented by making results for all
study outcomes available)
Check which outcomes were
collected in a trial with protocol
and/or trialist
✓
Include data for all relevant
outcomes
✓
* Only possible with AD reviews if detailed, high-quality data and/or other information can be obtained from trial protocols, trial reports or directly from trial
investigators.
doi:10.1371/journal.pmed.1001855.t002
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desire to bury unfavourable results, not including such trials could bias a meta-analysis,
whereas if it is to avoid providing trials of poor quality, then not including these trials might
make a meta-analysis more robust. Aiming to obtain a large proportion of the eligible trials
and participants will both counter bias and enable exploration of any quality issues and so
will likely provide the most reliable and precise assessment of the effects of an intervention.
Upwards of 90% of eligible participants has been suggested as a suitable target to achieve [3],
but 33% of a sample of IPD meta-analyses included less than 80% of the data requested [12].
Of course, if the available data can be shown to provide sufficient power to detect an effect reli-
ably, then a lower threshold may be acceptable. With substantial data missing, there is no guar-
antee that the meta-analysis results will be representative of those based on all data, making
data availability bias a possibility. This should be investigated (Table 2), preferably by compar-
ing or combining results based on IPD with those based on aggregate data, to check for coher-
ence and consistency [23]. For example, an IPD meta-analysis in non-Hodgkin lymphoma
suggested no clear improvement in survival with high-dose compared to conventional-dose
chemotherapy (hazard ratio = 1.14, 95% CI = 0.98–1.34, p = 0.401) [24]. Results based on
aggregate data were obtained for four of the five trials with missing IPD, and adding these gave
greater confidence in the conclusion that high-dose chemotherapy does not affect survival
(hazard ratio = 1.05, 95% CI = 0.92–1.19, p = 0.157) [24]. Funnel plots may also help indicate
the potential impact of both known and unknown missing trials on the results [25] but would
not be appropriate in a meta-analysis including less than ten trials [25] or few trials with statis-
tically significant results or one in which heterogeneity has been observed [26]. As a bare mini-
mum, the proportion of trials and participants for which IPD are available and the reasons for
unavailability of data should be a standard part of IPD meta-analysis reporting [27].
Was the Integrity of the IPD Checked?
While there is little opportunity to check the accuracy of aggregate data, IPD can be checked
for missing, invalid, out-of-range, or inconsistent items and for discrepancies with any trial
publication (Table 1, [3–5]). This would highlight, for example, a participant having an unusu-
ally old age or a date of randomisation prior to the date the trial started or instances in which
sequentially numbered participants were absent from a dataset. Although similar checks will
have been applied during trial conduct, occasionally anomalies still arise. Ideally, these should
be queried and, where possible, resolved with the trial's personnel, to improve data quality and
ensure that trials are represented accurately.
Were the Analyses Prespecified in Detail?
As IPD meta-analyses offer the potential for substantially greater numbers of analyses, there is
a greater risk that data might be interrogated repeatedly until the desired results are obtained,
these being the results that are published. Therefore, it is important that the detailed methods
of analysis are prespecified in a protocol or analysis plan and are clearly reported upon publica-
tion, including the following:
• primary and secondary outcomes and their definitions
• methods for analysis of efficacy/effectiveness, including those for exploring the impact of
trial or participant characteristics
• methods for quantifying and accounting for heterogeneity
• methods for checking IPD and assessing the risk of bias of trials
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This is not to say that unplanned analyses are unjustified or invalid; rather, they can play an
important role in explaining or adding to per-protocol results. However, such exploratory anal-
yses do need to be justified and clearly labelled as such in any report of the results.
Was the Risk of Bias of Included Trials Assessed?
Checking the quality of included trials is now a key component of systematic reviews, so that
any issues found can be either rectified or taken into account when interpreting the results, and
well-conducted IPD meta-analyses are no exception. For aggregate data reviews, this is fre-
quently achieved using the risk of bias tool developed by Cochrane [28,29], based on informa-
tion provided in trial reports. Seeking additional information from trialists can improve risk of
bias assessments associated with, for example, the randomisation procedures or the complete-
ness of outcome data [30,31]. Requesting such clarification tends to be more a feature of IPD
rather than aggregate data reviews. Furthermore, checking the IPD directly can provide more
reliable investigations of key potential biases, some of which might be reduced or alleviated in
the process (Table 2, [32]). As not all IPD meta-analyses include such assessments or may not
describe them explicitly, these are outlined below.
Were Randomisation, Allocation Concealment, and Blinding Assessed?
Checking that the methods of randomisation and allocation concealment are appropriate is
vital in ensuring that a trial provides a fair comparison of interventions (Table 2 [28]). The
IPD can be used, for example, to check whether participant characteristics are balanced by
arm, as would be expected, or to examine how participants were allocated to intervention arms
(Table 2). For example, in a trial in multiple myeloma, similar numbers of patients were allo-
cated to each arm until 1985, when, for a period of about six months, all patients were allocated
to the chemotherapy arm [3]. The investigators explained that this was because the radiother-
apy equipment was unavailable. Having IPD, it was possible to exclude this small group of non-
randomised patients, ensuring an unbiased analysis [3]. IPD meta-analyses employing such
checks safeguard against the inclusion of both nonrandomised trials and nonrandomised
participants.
The contact with trial staff that is intrinsic to collaborative IPD meta-analyses can provide
useful clarification of, for example, how participants and other study personnel were blinded,
allowing the risk of differential care or outcome assessments to be judged with more certainty
(Table 2). However, IPD cannot reduce bias or otherwise alter this aspect of trial conduct.
Were the IPD Checked to Ensure All Randomised Participants Were
Included?
Even with adequate randomisation methods, an unbiased comparison of intervention groups
can only be guaranteed if all randomised participants are analysed according to the interven-
tions initially assigned, i.e., using an intention-to-treat approach [33–35]. If patients drop out
or are excluded from the analysis of a trial in considerable numbers and/or disproportionately
by arm, this can cause attrition bias (Table 2, [36]), particularly if the reasons are related to the
intervention and outcome. For example, in 14 IPD cancer meta-analyses incorporating 133 tri-
als, between 0.3% and 38% of randomised patients were excluded from the original analyses
of 69% of trials, often with more being excluded from the research arms [37]. Around 1,800
excluded patients were reinstated when IPD were collected, and without them the meta-analy-
ses results would have been biased towards the research treatments, albeit to a small degree in
most cases [37]. However, for one meta-analysis in soft tissue sarcoma [38], the evidence for a
benefit of chemotherapy on survival was stronger when based only on those patients included
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in the original trial analyses (hazard ratio = 0.85, 95% CI = 0.72–1.00, p = 0.06), compared to
when all possible patients were included (hazard ratio = 0.90, 95% CI = 0.77–1.04, p = 0.16)
[37], which could have affected the clinical interpretation. Thus, to help minimise and poten-
tially eliminate attrition bias, IPD should be checked to ensure that data on all or as many
randomised participants as possible are included. If there is good reason to exclude certain par-
ticipants, then this should be prespecified as part of the meta-analysis eligibility criteria and
such exclusions applied consistently across trials, to avoid bias [37]. Taking this approach of
making consistent (clinically plausible) exclusions across trials in the sarcoma meta-analysis
produced very similar results (hazard ratio = 0.91, CI = 0.78–1.07, p = 0.28) to those based on
all patients.
Were All Relevant Outcomes Included?
Outcome reporting bias arises if the effect of an intervention varies by outcome, and only par-
ticular outcomes are reported, for example, those showing benefit (Table 2). Such bias can be
compounded in systematic reviews of published aggregate data [39], because by definition they
can only include reported outcomes. Obtaining additional outcome data, as part of the IPD col-
lection process, can resolve this problem, as demonstrated in a systematic review of laparo-
scopic versus open surgery for the repair of inguinal hernia. Based on published aggregate data
from the three trials that reported it, the risk of persistent pain was found to be significantly
greater with laparoscopic repair (odds ratio = 2.03, 95% CI = 1.03–4.01) [40]. Yet, when IPD
from a further 17 trials (that did not publish results for this outcome) were added, the com-
bined results showed that the risk of persistent pain was actually less with laparoscopic repair
(odds ratio = 0.54, 95% CI = 0.46–0.64, p< 0.001) [40]. Moreover, the much narrower confi-
dence intervals show that these results are far more reliable. Therefore, to avoid bias and pro-
vide a balanced view of benefits and harms, IPD meta-analyses should include data on all
available key outcomes, bearing in mind that there may be some that have been collected but
not reported in the original trial publication.
Was the Quality of Time-to-Event Outcome Data Checked?
For time-to-event outcomes, such as survival or time to resolution of symptoms, bias can occur
if participants are observed more frequently or for a longer duration on one intervention arm
compared to another. This is because it can make it appear that event rates are higher in that
arm (Table 2). Even if follow up is similar by arm, trials that stop early or have follow-up that is
too short might produce results that are transitory or fail to pick up long-term effects. For
example, in an IPD meta-analysis of chemotherapy in addition to local treatment for soft tissue
sarcoma [38], median follow up for survival was reported for seven of the included trials and
ranged from 16 to 64 months. Investigators supplying IPD were able to extend the median
follow up for these trials to between 74 and 204 months [32], which allowed a more reliable
examination of the effects of chemotherapy in the longer term [38]. Thus, with IPD, both the
pattern and extent of follow up should be checked, and where relevant, additional follow up
obtained to rectify any imbalances and provide more up-to-date and reliable outcome data
(Table 2). Of course, this may not be practical or necessary if most or all events have already
taken place.
Were the Methods of Analysis Appropriate?
The outcomes and effect measures of interest in an IPD meta-analysis are often the same as
those used in a meta-analysis of aggregate data, such as relative risks, odds ratios, or risk differ-
ences for dichotomous outcomes; mean differences for continuous outcomes; and hazard ratios
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for time-to-event outcomes. However, having IPD can allow harmonisation of outcome defini-
tions across trials, analytical assumptions to be checked, and effect measures to be derived
directly from the analysis of the collated data (Table 1), with no need to rely on the original
trial analyses. Alternative effect measures can be computed and synthesised, if desired. As
more complex, nonstandard methods may be used for meta-analyses based on IPD, we outline
some key principles to look for, noting that analyses to investigate publication and data avail-
ability bias have already been discussed.
Were the Methods of Assessing the Overall Effects of Interventions
Appropriate?
As participants in an IPD meta-analysis are recruited according to different trial protocols,
combining IPD across trials, as though it comes from a single “mega” trial, could lead to biased
comparisons of interventions and overprecise estimates of effect (Table 2). For example, the
effect of nicotine gum on smoking cessation was shown to be severely attenuated and too pre-
cise when the analysis treated the IPD as though it belonged to one trial (odds ratio = 1.40, 95%
CI = 1.02–1.92) rather than multiple trials (odds ratio = 1.80, 95% CI 1.29–2.52) [41]. Thus, a
key component of the analysis is to stratify or account for clustering of participants [41]. To
date, two-stage meta-analysis of IPD is the most common way of combining data while pre-
serving participants’ trial membership [42,43]. In the first stage, estimates of effect are derived
from the IPD for each trial, and in the second stage, these are combined using methods analo-
gous to most meta-analyses of aggregate data. Thus, standard fixed-effect (e.g., Peto, Mantel-
Haenszel, and inverse-variance [44,45]) and random effects methods (e.g., Dersimonian and
Laird [46]) can be utilised to derive estimates of the intervention effect, with the latter helping
to account for any differences in effect across trials (heterogeneity), and standard statistics
(e.g., study weights and I2) and forest plots can be produced.
Alternatively, a one-stage model [42] can be used to estimate intervention effects while
stratifying or otherwise accounting for differences between trials [47–50]. This is typically a
regression model such as linear, logistic, or Cox regression, with either a separate term for each
trial or one that varies across trials via a random effect. Based on theoretical considerations
[51–53], simulation studies [43,54], and case studies in epilepsy [54], cancer [43], maternal
health [55], and childhood infections [56], one-stage and two-stage methods usually produce
similar meta-analysis results. For example, the effects of anti-platelets on pre-eclampsia in
pregnancy from a two-stage (relative risk = 0.90, 95% CI = 0.83–0.96) and one-stage model
(relative risk = 0.90, 95% CI = 0.83–0.97) were almost identical [55]. However, when included
studies are small and/or when an effect is large [43,54] or events are rare [57], there can be
some bias in a two-stage analysis, because some of the assumptions in the second stage are
potentially inappropriate. Thus, for many, the one-stage approach is preferable, although it
makes it more difficult to calculate the standard meta-analysis statistics directly, and the com-
plexity can make interpretation of the results less accessible to those who are used to the more
familiar two-stage approach. Hence, researchers often will do a one-stage analysis to obtain
estimates of effect and use a two-stage analysis to obtain further statistics and forest plots. It is
important, therefore, that the choice of one or two-stage analysis is specified in advance or that
results for both approaches are reported [55].
Were the Methods of Assessing If Effects of Interventions Varied by Trial
or Participant Characteristics Appropriate?
Exploring whether intervention effects vary or are modified by trial characteristics, such as the
duration of the intervention or dose of drugs, and the nature of these interactions is another
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important aspect of meta-analysis. For both aggregate data and IPD, it is reasonable to investi-
gate these sorts of trial-level interactions using subgroup analyses, whereby intervention effects
are compared between groups of trials, or meta-regression in which the change in overall inter-
vention effect in relation to trial characteristics is investigated [58].
A frequent motivation, however, for collecting IPD is the ability to investigate interactions
between overall intervention effects and individual participant-level characteristics, such as age
or stage of disease or risk of an outcome. This is important for clinical decision-making and
policy, in which the aim is to target interventions at those who are most likely to benefit or are
least likely to be harmed by them. Single trials are typically underpowered to detect such inter-
actions, and meta-regression of aggregate data is usually inadequate for the purpose, because it
also has low power and only permits trial-level interactions between overall intervention effects
and summaries of participant characteristics, such as mean age. The latter may not reflect the
genuine relationships between intervention effects and individual participant characteristics
(Table 2, [59]). Similarly, comparing a two-stage IPD meta-analysis of intervention effects in
one participant group with another, for example, effects in men and women, using a test for
interaction (sometimes called subgroup analyses) is common in IPD meta-analysis but prone
to bias and best avoided [60]. Rather, the focus should be on estimating the individual partici-
pant-level interactions, which is usually only possible with IPD. Again, this can be achieved in
two stages, by estimating the interactions separately for each trial in the first stage and then
pooling these across trials in the second stage, using meta-analysis techniques [60], For exam-
ple, using this methodology, there was no clear evidence of a relationship between lymph node
involvement and the effect of postoperative radiotherapy on survival in non-small cell lung
cancer and (interaction hazard ratio = 0.91, 95% CI = 0.74–1.11, p = 0.34) [60]. In contrast,
using the flawed subgroup analysis approach, the effect of postoperative radiotherapy on sur-
vival was erroneously found to vary with the number of lymph nodes affected (chi-square test
for trend, df = 1, p = 0.016) [61].
Alternatively, a one-stage approach that incorporates an intervention by participant covari-
ate interaction term in a regression model while also accounting for clustering of patients
within trials (as described above) can be used. This must carefully separate out this individual
participant-level interaction from any trial-level interactions [60,62]. Uniquely, the one-stage
approach allows the relative influence of multiple trial and patient characteristics on any inter-
vention effect to be considered simultaneously, which can help deal with confounding [63] and
may provide greater clinical insight. When there is no particular evidence of a differential effect
by trial or participant characteristic, emphasis should be placed on the overall result.
To allow appropriate interpretation, results of all such analyses should be reported in full
and should include effect sizes and confidence intervals for each meta-analysis, measures of
statistical heterogeneity, and interactions between intervention effects and trial or participant
characteristics [27].
Discussion
We have provided guidance to help those using the results of IPD meta-analyses to inform pol-
icy, practice, or research, and those reviewing grant applications or manuscripts relating to
IPD meta-analyses, to assess critically their quality (summarised in Box 1). Expert opinion may
be required to navigate the more complicated statistical methods. Given that collecting IPD
can be a lengthy and costly endeavour, additionally funders might want to ask researchers to
explain what value IPD will bring over aggregate data and whether applicants have established
the feasibility of the IPD approach, for example, by contacting trial investigators to see whether
they are willing and able to provide data [64]. Realistically, many IPD meta-analyses will not be
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Box 1. Key Questions to Ask When Appraising an IPD Meta-
analysis
1. Is the IPD meta-analysis part of a systematic review?
a Does it have a clear research question qualified by explicit eligibility criteria?
b Does it have a systematic and comprehensive search strategy for identifying trials?
c Does it have a consistent approach to data collection?
d Does it assess the “quality” or risk of bias of included trials?
e Are all the methods prespecified in a protocol?
f Has the protocol been registered or otherwise made available?
2. Were all eligible trials identified?
a Were fully published trials identified?
b Were trials published in the grey literature identified?
c Were unpublished trials identified?
3. Were IPD obtained for most trials?
a Were IPD obtained for a large proportion of the eligible trials?
b Was an assessment of the potential impact of missing trials undertaken?
c Were the reasons for not obtaining IPD provided?
4. Was the integrity of the IPD checked?
a Were the data checked for missing, invalid out-of-range, or inconsistent items?
b Were there any discrepancies with the trial report (if available)?
c Were any issues queried and, if possible, resolved?
5. Were the analyses prespecified in detail?
a Were the detailed analysis methods included in a protocol or analysis plan?
b Were the outcomes and methods for analysing the effects of interventions, quantify-
ing and accounting for heterogeneity, and assessing risk of bias included?
6. Was the risk of bias of included trials assessed?
a Were the randomisation, allocation concealment, and blinding assessed?
b Were the IPD checked to ensure all (or most) randomised participants were
included?
c Were all relevant outcomes included?
d Was the quality of time-to-event-outcome data checked?
7. Were the methods of analysis appropriate?
a Were the methods of assessing the overall effects of interventions appropriate?
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perfect in all respects, but if they are conducted in the context of a systematic review, include a
high-proportion of good-quality data and use appropriate analyses, they will most likely pro-
vide reliable assessments of the effects of interventions.
With the expected increase in the use of IPD in systematic reviews, as a consequence of
the drive for greater sharing of data held within trials, guidance on appropriate methodology
will become ever more valuable. Many of the advantages and pitfalls we describe in relation to
standard IPD meta-analyses, are transferrable to network IPD meta-analysis of efficacy, and
elements of this guidance relating to trial identification, data quality and risk of bias will fre-
quently apply. However, additional research and guidance on appropriate analytical ap-
proaches is needed. IPD is also being collected to improve the quality of systematic reviews of
diagnostic and prognostic studies [65–67], and to allow necessarily complex, multi-parameter,
meta-analysis methods [68] in these reviews. However, such methodology is less well estab-
lished, and will differ in additional respects. Hence, more specific guidance is needed to facili-
tate appraisal of these sorts of IPD meta-analyses.
Increasingly, planned methods for IPD meta-analyses can be found in protocols that are
registered in the PROSPERO International Prospective Register of Systematic Reviews [69],
i. Did researchers stratify or account for clustering of participants within trials
using either a one- or two-stage approach to meta-analysis?
ii. Was the choice of one- or two-stage analysis specified in advance and/or
results for both approaches provided?
b Were the methods of assessing whether effects of interventions varied by trial char-
acteristics appropriate?
i. Did researchers compare treatment effects between subgroups of trials or use
meta-regression to assess whether the overall treatment effect varied in rela-
tion to trial characteristics?
c Were the methods of assessing whether effects of interventions vary by participant
characteristics appropriate?
i. Did researchers estimate an interaction separately for each trial and combine
these across trials in a two-stage fixed effect or random effects meta-analysis?
Or;
ii. Did researchers incorporate one or more a treatment by participant covariate
interaction terms in a regression model, whilst also accounting for clustering
of participant, separating out this individual participant-level interaction
from any trial-level interactions?
d If there was no evidence of a differential effect by trial or participant characteristic,
was emphasis placed on the overall result?
e Were exploratory analyses highlighted as such?
8. Does any report of the results adhere to the Preferred Reporting Items for a System-
atic review and Meta-analysis of IPD (The PRISMA-IPD Statement) [27]?
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published or made available by other means. This practice needs to be encouraged, as there is
empirical evidence that reporting of search strategies, data availability [12,42] and methods of
analysis [42] is variable, and anecdotal evidence that the methods for checking data and risk of
bias are frequently absent from IPD meta-analyses publications. Although missing information
can be sought from researchers, to enable discerning appraisal, clearly reporting should also be
improved. Researchers conducting PD meta-analyses often target high impact print journals
[70], and restrictions on the number of words, figures and tables, may have led them to con-
dense or omit particular methods or results. They can now utilise online journals, and the
increasing opportunities offered by print journals to publish material online, to alleviate these
issues. Journals can help by being responsive to the need for full reporting of IPD meta-analy-
ses. Moreover, those conducting IPD meta-analyses should follow the PRISMA reporting
guidelines developed specifically for the IPD approach [27].
Taking steps to identify well designed and conducted IPD meta-analyses of efficacy will
help ensure that clinical practice and research is informed by robust evidence about the effect
of interventions.
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